Key result
Heparin use in acute ischemic stroke persists despite only ~6% of surveyed neurologists believing it works.
Why the study?
The opinions and clinical practices of neurologists regarding antithrombotic drug use in acute ischemic stroke treatment were uncertain.
Cross-Sectional (n=247)
Yes
This survey highlights a significant discrepancy between the frequent clinical use of heparin in acute ischemic stroke and neurologists' doubts regarding its efficacy and safety, underscoring the need for definitive clinical trials.
Heparin use in acute stroke outpaces neurologist confidence; leaves open the need for RCTs to align practice with evidence.
In an attempt to determine the opinions and practices of neurologists regarding the use of antithrombotic drugs in the treatment of acute ischemic stroke, we conducted a survey of 349 randomly selected neurologists from throughout the United States. Responses were received from 247 (71%), and 219 identified themselves as primary or consulting physicians for patients with acute ischemic stroke. During the previous 12 months, these 219 physicians estimated that they had seen a total of 14,636 patients within 24 hours of acute ischemic stroke, and 22% of these patients were treated with heparin. The most frequently reported indications were prevention of recurrent cerebral embolism (82% of physicians) and progressing stroke (70%). Despite the frequent use of heparin, only 6.4% of neurologists felt that it has been shown to be effective, and 16.4% felt that it has been shown to be of no value. The primary concern about the use of heparin was lack of proven efficacy in 48% and safety concerns in 41%. Results of a future trial testing the efficacy of antithrombotic drugs would be useful for most neurologists in their management of patients with acute or progressing ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Marsh et al. (1989) conducted a cross-sectional in Acute ischemic stroke (n=247). Antithrombotic drugs (heparin) was evaluated on Opinions and practices regarding the use of antithrombotic drugs. Despite estimating that 22% of acute ischemic stroke patients received heparin, only 6.4% of surveyed US neurologists believed it to be effective, with 48% citing a lack of proven efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: